Unknown

Dataset Information

0

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients.

ABSTRACT: BACKGROUND/AIM:Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. PATIENTS AND METHODS:High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. RESULTS:Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). CONCLUSION:A predictive miRNA associated with progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.

SUBMITTER: Kovacova J 

PROVIDER: S-EPMC6727077 | biostudies-literature | 2019 Sep-Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients.

Kovacova Julia J   Juracek Jaroslav J   Poprach Alexandr A   Kopecky Jindrich J   Fiala Ondrej O   Svoboda Marek M   Fabian Pavel P   Radova Lenka L   Brabec Petr P   Buchler Tomas T   Slaby Ondrej O  

Cancer genomics & proteomics 20190901 5

<h4>Background/aim</h4>Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients.<h4>Patients and methods</h4>High-throughput miRNA microarray profiling was performed on a co  ...[more]

Similar Datasets

Unknown Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
| S-EPMC3219862 | biostudies-literature
Unknown Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
| S-EPMC5032140 | biostudies-literature
Unknown Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.
| S-EPMC6736765 | biostudies-literature
Unknown miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
| S-EPMC4817948 | biostudies-literature
Unknown Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment.
| S-EPMC8467952 | biostudies-literature
Unknown Sunitinib in the treatment of metastatic renal cell carcinoma.
| S-EPMC5117167 | biostudies-literature
Unknown Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma.
| S-EPMC7469516 | biostudies-literature
Unknown Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients.
| S-EPMC5496476 | biostudies-other
Proteomics Transgelin contributes to a poor response of metastatic renal cell carcinoma to sunitinib treatment
2021-11-03 | PXD027065 | Pride
Unknown Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma.
| S-EPMC6558298 | biostudies-literature